BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24762994)

  • 1. [Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia].
    Liu SG; Gao C; Li ZG; Li WJ; Cui L; Zhao XX; Zheng HY; Wu MY; Zhang RD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):291-7. PubMed ID: 24762994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.
    Huang Z; Tong HF; Li Y; Qian JC; Wang JX; Wang Z; Ruan JC
    Med Sci Monit; 2016 Dec; 22():4967-4973. PubMed ID: 27987364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):283-9. PubMed ID: 24908438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The mbr-FPGS efficient expression plasmid enhances the sensitivity of Jurkat cells to methotrexate].
    Hu WJ; Sun YJ
    Yi Chuan; 2012 Jun; 34(6):705-10. PubMed ID: 22698741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
    Leclerc GJ; Mou C; Leclerc GM; Mian AM; Barredo JC
    Leukemia; 2010 Mar; 24(3):552-62. PubMed ID: 20072153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Liu SG; Gao C; Zhang RD; Jiao Y; Cui L; Li WJ; Chen ZP; Wu MY; Zheng HY; Zhao XX; Yue ZX; Li ZG
    Cancer Cell Int; 2013 Oct; 13(1):107. PubMed ID: 24168269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.
    Wojtuszkiewicz A; Raz S; Stark M; Assaraf YG; Jansen G; Peters GJ; Sonneveld E; Kaspers GJ; Cloos J
    Int J Cancer; 2016 Apr; 138(7):1645-56. PubMed ID: 26547381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.
    Xue Y; Rong L; Tong N; Wang M; Zhang Z; Fang Y
    Int J Clin Exp Pathol; 2015; 8(9):11594-600. PubMed ID: 26617896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Screening and Association Study of the Folylpolyglutamate Synthetase (FPGS) Gene with Susceptibility to Childhood Acute Lymphoblastic Leukemia.
    Piwkham D; Siriboonpiputtana T; Beuten J; Pakakasama S; Gelfond JA; Paisooksantivatana K; Tomlinson GE; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2015; 16(11):4727-32. PubMed ID: 26107232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
    Tulstrup M; Moriyama T; Jiang C; Grosjean M; Nersting J; Abrahamsson J; Grell K; Hjalgrim LL; Jónsson ÓG; Kanerva J; Lund B; Nielsen SN; Nielsen RL; Overgaard U; Quist-Paulsen P; Pruunsild K; Vaitkeviciene G; Wolthers BO; Zhang H; Gupta R; Yang JJ; Schmiegelow K
    Blood; 2020 Sep; 136(10):1161-1168. PubMed ID: 32391884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
    Rots MG; Pieters R; Peters GJ; Noordhuis P; van Zantwijk CH; Kaspers GJ; Hählen K; Creutzig U; Veerman AJ; Jansen G
    Blood; 1999 Mar; 93(5):1677-83. PubMed ID: 10029597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.
    Yu SL; Zhang H; Ho BC; Yu CH; Chang CC; Hsu YC; Ni YL; Lin KH; Jou ST; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Pui CH; Yang JJ; Zhang J; Lin DT; Lin SW; Ma X; Yang YL
    Sci Rep; 2020 Jul; 10(1):12074. PubMed ID: 32694622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.
    Liu SG; Gao C; Zhang RD; Zhao XX; Cui L; Li WJ; Chen ZP; Yue ZX; Zhang YY; Wu MY; Wang JX; Li ZG; Zheng HY
    Oncotarget; 2017 Jun; 8(23):37761-37772. PubMed ID: 28525903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
    Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of
    Kodidela S; Dorababu P; Thakkar DN; Dubashi B; Sundaram R; Muralidharan N; Nidanapu RP; Aribandi A; Pradhan SC; Uppugunduri CRS
    Genes (Basel); 2020 May; 11(6):. PubMed ID: 32481505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia.
    Gajjar A; Ribeiro RC; Mahmoud HH; Sandlund JT; Liu Q; Furman WL; Santana VM; Crist WM; Rivera GK; Pui CH
    Cancer; 1996 Dec; 78(11):2437-42. PubMed ID: 8941016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.